BACKGROUND Fecal calprotectin (FCP), magnetic resonance enterography (MRE), and colonoscopy are complementary biometric tests that are used to assess patients with Crohn's Disease (CD). While prior studies have evaluated the association between combinations of these tests, no study has established a correlation between all three: FCP, MRE, and colonoscopy. We prospectively investigated if there is correlation between these three tests, which may result in improved clinical outcomes that can then be used to streamline patient monitoring and treatment modification. METHODS One hundred fifty-six patients with colonic CD were prospectively examined between March 2017 and December 2018. FCP levels, MRE, and colonoscopy were assessed in parallel on all 156 patients. Clinical CD activity was measured with the Crohn's Disease Activity Index (CDAI). CD activity with FCP was measured with a quantitative immunoassay. CD activity on MRE was measured with the Magnetic Resonance Index of Activity (MaRIA). CD activity on colonoscopy was measured with the Crohn's Disease Endoscopic Index of Severity (CDEIS). RESULTS One hundred twelve patients (72%) had active disease (Crohn's Disease Activity Index > 150) and 44 patients (28%) were in clinical remission disease (Crohn's Disease Activity Index < 150). FCP levels, MaRIA, and CDEIS are highly correlated with positive and significant Pearson and Spearman coefficients, respectively (P < 0.0001), in univariate analyses. Regression analysis (multivariate analyses) demonstrates significant, positive correlation between FCP and MaRIA (r = 1.07, P < 0.0001) and between FCP and CDEIS (r = 0.71, P = 0.03), and between. MaRIA and CDEIS (r = 0.63, P = 0.01). CONCLUSIONS FCP levels significantly correlate with the degree of active inflammation in patients with colonic Crohn's Disease. Improved clinical results may be achieved by using a biometric strategy that incorporates FCP, colonoscopy, and MRE together. This strategy may in-turn be used in the future to streamline monitoring disease activity and adjustment of therapy to improve long term patient outcomes.

中文翻译：

---

磁共振肠造影，结肠镜检查和粪便钙卫蛋白与结肠克罗恩氏病相关。

背景技术粪便钙卫蛋白（FCP），磁共振肠造影（MRE）和结肠镜检查是用于评估患有克罗恩病（CD）的患者的辅助生物测定测试。尽管先前的研究已经评估了这些测试的组合之间的关联，但尚无研究在FCP，MRE和结肠镜检查这三个之间建立关联。我们前瞻性地研究了这三个测试之间是否存在相关性，这可能会导致改善临床结果，从而可用于简化患者监测和治疗修改。方法在2017年3月至2018年12月之间对156例结肠CD患者进行了前瞻性检查。对156例患者的FCP水平，MRE和结肠镜检查进行了平行评估。临床CD活性用Crohn's测定 疾病活动指数（CDAI）。用定量免疫测定法测量FCP的CD活性。用磁共振活性指数（MaRIA）测量MRE上的CD活性。结肠镜检查中的CD活性用克罗恩病内窥镜检查严重度指数（CDEIS）进行测量。结果112例（72％）患有活动性疾病（克罗恩病活动指数> 150），44例（28％）患有临床缓解疾病（克罗恩病活动指数<150）。在单变量分析中，FCP水平，MaRIA和CDEIS分别与正和显着的Pearson和Spearman系数高度相关（P <0.0001）。回归分析（多元分析）表明，FCP和MaRIA之间（r = 1.07，P <0.0001）以及FCP和CDEIS之间（r = 0.71，P = 0）具有显着正相关。03），以及之间。MaRIA和CDEIS（r = 0.63，P = 0.01）。结论FCP水平与结肠克罗恩病患者的活动性炎症程度显着相关。通过使用结合了FCP，结肠镜检查和MRE的生物识别策略，可以提高临床效果。将来可能会再次使用此策略来简化疾病活动的监测和治疗的调整，以改善长期患者的预后。